|
1
|
Lobo N, Mount C, Omar K, Nair R,
Thurairaja R and Khan MS: Landmarks in the treatment of
muscle-invasive bladder cancer. Nat Rev Urol. 14:565–574. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Keegan KA, Zaid HB, Patel SG and Chang SS:
Increasing utilization of neoadjuvant chemotherapy for
muscle-invasive bladder cancer in the United States. Curr Urol Rep.
15:3942014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Amable L: Cisplatin resistance and
opportunities for precision medicine. Pharmacol Res. 106:27–36.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel- Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martens-Uzunova ES, Bottcher R, Croce CM,
Jenster G, Visakorpi T and Calin GA: Long noncoding RNA in
prostate, bladder, and kidney cancer. Eur Urol. 65:1140–1151. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chandra Gupta S and Nandan Tripathi Y:
Potential of long non-coding RNAs in cancer patients: From
biomarkers to therapeutic targets. Int J Cancer. 140:1955–1967.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Taheri M, Omrani MD and Ghafouri-Fard S:
Long non-coding RNA expression in bladder cancer. Biophys Rev.
10:1205–1213. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bejerano G, Pheasant M, Makunin I, Stephen
S, Kent WJ, Mattick JS and Haussler D: Ultraconserved elements in
the human genome. Science. 304:1321–1325. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lujambio A, Portela A, Liz J, Melo SA,
Rossi S, Spizzo R, Croce CM, Calin GA and Esteller M: CpG island
hypermethylation-associated silencing of non-coding RNAs
transcribed from ultraconserved regions in human cancer. Oncogene.
29:6390–6401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goto K, Ishikawa S, Honma R, Tanimoto K,
Sakamoto N, Sentani K, Oue N, Teishima J, Matsubara A and Yasui W:
The transcribed-ultraconserved regions in prostate and gastric
cancer: DNA hypermethylation and microRNA-associated regulation.
Oncogene. 35:3598–3606. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ferdin J, Nishida N, Wu X, Nicoloso MS,
Shah MY, Devlin C, Ling H, Shimizu M, Kumar K, Cortez MA, et al:
HINCUTs in cancer: Hypoxia-induced noncoding ultraconserved
transcripts. Cell Death Differ. 20:1675–1687. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Marini A, Lena AM, Panatta E, Ivan C, Han
L, Liang H, Annicchiarico-Petruzzelli M, Di Daniele N, Calin GA,
Candi E, et al: Ultraconserved long non-coding RNA uc.63 in breast
cancer. Oncotarget. 8:35669–35680. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sekino Y, Sakamoto N, Goto K, Honma R,
Shigematsu Y, Sentani K, Oue N, Teishima J, Matsubara A and Yasui
W: Transcribed ultraconserved region Uc.63+ promotes resistance to
docetaxel through regulation of androgen receptor signaling in
prostate cancer. Oncotarget. 8:94259–94270. 2017.PubMed/NCBI
|
|
15
|
Hayashi T, Seiler R, Oo HZ, Jäger W,
Moskalev I, Awrey S, Dejima T, Todenhöfer T, Li N, Fazli L, et al:
Targeting HER2 with T-DM1, an antibody cytotoxic drug conjugate, is
effective in HER2 over expressing bladder cancer. J Urol.
194:1120–1131. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Oue N, Naito Y, Hayashi T, Takigahira M,
Kawano-Nagatsuma A, Sentani K, Sakamoto N, Zarni Oo H, Uraoka N,
Yanagihara K, et al: Signal peptidase complex 18, encoded by
SEC11A, contributes to progression via TGF-alpha secretion in
gastric cancer. Oncogene. 33:3918–3926. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sekino Y, Oue N, Shigematsu Y, Ishikawa A,
Sakamoto N, Sentani K, Teishima J, Matsubara A and Yasui W: KIFC1
induces resistance to docetaxel and is associated with survival of
patients with prostate cancer. Urol Oncol. 35:31 e13–31 e20. 2017.
View Article : Google Scholar
|
|
18
|
Miyamoto H, Zheng Y and Izumi K: Nuclear
hormone receptor signals as new therapeutic targets for urothelial
carcinoma. Curr Cancer Drug Targets. 12:14–22. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miyamoto H, Yang Z, Chen YT, Ishiguro H,
Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, et al:
Promotion of bladder cancer development and progression by androgen
receptor signals. J Natl Cancer Inst. 99:558–568. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shiota M, Takeuchi A, Yokomizo A,
Kashiwagi E, Tatsugami K, Kuroiwa K and Naito S: Androgen receptor
signaling regulates cell growth and vulnerability to doxorubicin in
bladder cancer. J Urol. 188:276–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kashiwagi E, Ide H, Inoue S, Kawahara T,
Zheng Y, Reis LO, Baras AS and Miyamoto H: Androgen receptor
activity modulates responses to cisplatin treatment in bladder
cancer. Oncotarget. 7:49169–49179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fabris L and Calin GA: Understanding the
genomic ultraconservations: T-UCRs and cancer. Int Rev Cell Mol
Biol. 333:159–172. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Olivieri M, Ferro M, Terreri S, Durso M,
Romanelli A, Avitabile C, De Cobelli O, Messere A, Bruzzese D,
Vannini I, et al: Long non-coding RNA containing ultraconserved
genomic region 8 promotes bladder cancer tumorigenesis. Oncotarget.
7:20636–20654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y, Izumi K and Miyamoto H: The role of
the androgen receptor in the development and progression of bladder
cancer. Jpn J Clin Oncol. 42:569–577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shiota M, Kiyoshima K, Yokomizo A,
Takeuchi A, Kashiwagi E, Dejima T, Takahashi R, Inokuchi J,
Tatsugami K and Eto M: Suppressed recurrent bladder cancer after
androgen suppression with androgen deprivation therapy or
5alpha-reductase inhibitor. J Urol. 197:308–313. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Izumi K, Ito Y, Miyamoto H, Miyoshi Y, Ota
J, Moriyama M, Murai T, Hayashi H, Inayama Y, Ohashi K, et al:
Expression of androgen receptor in non-muscle-invasive bladder
cancer predicts the preventive effect of androgen deprivation
therapy on tumor recurrence. Oncotarget. 7:14153–14160. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiong Y, Wang L, Li Y, Chen M, He W and Qi
L: The long non-coding RNA XIST interacted with MiR-124 to modulate
bladder cancer growth, invasion and migration by targeting androgen
receptor (AR). Cell Physiol Biochem. 43:405–418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Calin GA, Liu CG, Ferracin M, Hyslop T,
Spizzo R, Sevignani C, Fabbri M, Cimmino A, Lee EJ, Wojcik SE, et
al: Ultraconserved regions encoding ncRNAs are altered in human
leukemias and carcinomas. Cancer Cell. 12:215–229. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen L, Chang WC, Hung YC, Chang YY, Bao
BY, Huang HC, Chung WM, Shyr CR and Ma WL: Androgen receptor
increases CD133 expression and progenitor-like population that
associate with cisplatin resistance in endometrial cancer cell
line. Reprod Sci. 21:386–394. 2014. View Article : Google Scholar : PubMed/NCBI
|
